The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Clinical activity of enzalutamide (Enza) pre- and post-docetaxel in men with metastatic castration-resistant prostate cancer (mCRPC).
Rosa Nadal
No relevant relationships to disclose
Zhe Zhang
No relevant relationships to disclose
Hitesh Raheja
No relevant relationships to disclose
Mario A. Eisenberger
No relevant relationships to disclose
Emmanuel S. Antonarakis
No relevant relationships to disclose